Literature DB >> 20100877

In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria.

D M Citron1, K L Tyrrell, C V Merriam, E J C Goldstein.   

Abstract

The in vitro activities of ceftaroline, a novel, parenteral, broad-spectrum cephalosporin, and four comparator antimicrobials were determined against anaerobic bacteria. Against Gram-positive strains, the activity of ceftaroline was similar to that of amoxicillin-clavulanate and four to eight times greater than that of ceftriaxone. Against Gram-negative organisms, ceftaroline showed good activity against beta-lactamase-negative strains but not against the members of the Bacteroides fragilis group. Ceftaroline showed potent activity against a broad spectrum of anaerobes encountered in respiratory, skin, and soft tissue infections.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20100877      PMCID: PMC2849373          DOI: 10.1128/AAC.01788-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  18 in total

1.  Prevalence of antibiotic resistance in anaerobic bacteria: worrisome developments.

Authors:  David W Hecht
Journal:  Clin Infect Dis       Date:  2004-06-03       Impact factor: 9.079

2.  Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains.

Authors:  Helio S Sader; Thomas R Fritsche; Koné Kaniga; Yigong Ge; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

Review 3.  Anaerobic bacterial infections of the lung and pleural space.

Authors:  J G Bartlett
Journal:  Clin Infect Dis       Date:  1993-06       Impact factor: 9.079

4.  Bacteriology of anaerobic pleuropulmonary infections: preliminary report.

Authors:  M Marina; C A Strong; R Civen; E Molitoris; S M Finegold
Journal:  Clin Infect Dis       Date:  1993-06       Impact factor: 9.079

5.  A retrospective review of cases of anaerobic empyema and update of bacteriology.

Authors:  R Civen; H Jousimies-Somer; M Marina; L Borenstein; H Shah; S M Finegold
Journal:  Clin Infect Dis       Date:  1995-06       Impact factor: 9.079

6.  General microbiology and in vitro susceptibility of anaerobes isolated from complicated skin and skin-structure infections in patients enrolled in a comparative trial of ertapenem versus piperacillin-tazobactam.

Authors:  Ellie J C Goldstein; Diane M Citron; C Vreni Merriam; Yumi Warren; Kerin L Tyrrell; Richard M Gesser
Journal:  Clin Infect Dis       Date:  2002-09-01       Impact factor: 9.079

Review 7.  Aspiration pneumonia.

Authors:  S M Finegold
Journal:  Rev Infect Dis       Date:  1991 Jul-Aug

8.  In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.

Authors:  Cédric Jacqueline; Jocelyne Caillon; Virginie Le Mabecque; Anne-Françoise Miègeville; Antoine Hamel; Denis Bugnon; James Yigong Ge; Gilles Potel
Journal:  Antimicrob Agents Chemother       Date:  2007-06-25       Impact factor: 5.191

9.  Activity of the new cephalosporin ceftaroline against bacteraemia isolates from patients with community-acquired pneumonia.

Authors:  Ian Morrissey; Yigong Ge; Regina Janes
Journal:  Int J Antimicrob Agents       Date:  2009-02-08       Impact factor: 5.283

10.  In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.

Authors:  Shazad Mushtaq; Marina Warner; Yigong Ge; Koné Kaniga; David M Livermore
Journal:  J Antimicrob Chemother       Date:  2007-06-04       Impact factor: 5.790

View more
  13 in total

Review 1.  Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.

Authors:  Thomas P Lodise; Donald E Low
Journal:  Drugs       Date:  2012-07-30       Impact factor: 9.546

2.  In vitro activity of ceftaroline against a broad spectrum of recent clinical anaerobic isolates.

Authors:  David R Snydman; Nilda V Jacobus; Laura A McDermott
Journal:  Antimicrob Agents Chemother       Date:  2010-11-01       Impact factor: 5.191

Review 3.  Ceftaroline fosamil: a review of its use in the treatment of complicated skin and soft tissue infections and community-acquired pneumonia.

Authors:  James E Frampton
Journal:  Drugs       Date:  2013-07       Impact factor: 9.546

4.  Ampicillin in Combination with Ceftaroline, Cefepime, or Ceftriaxone Demonstrates Equivalent Activities in a High-Inoculum Enterococcus faecalis Infection Model.

Authors:  Megan K Luther; Louis B Rice; Kerry L LaPlante
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

5.  Ceftaroline versus isolates from animal bite wounds: comparative in vitro activities against 243 isolates, including 156 Pasteurella species isolates.

Authors:  Ellie J C Goldstein; Diane M Citron; C Vreni Merriam; Kerin L Tyrrell
Journal:  Antimicrob Agents Chemother       Date:  2012-10-01       Impact factor: 5.191

Review 6.  Ceftaroline Fosamil: A Review in Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia.

Authors:  Lesley J Scott
Journal:  Drugs       Date:  2016-11       Impact factor: 9.546

7.  In vitro activity of ceftaroline against gram-positive and gram-negative pathogens isolated from patients in Canadian hospitals in 2009.

Authors:  James A Karlowsky; Heather J Adam; Melanie R Decorby; Philippe R S Lagacé-Wiens; Daryl J Hoban; George G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2011-03-14       Impact factor: 5.191

8.  Ceftaroline: A New Cephalosporin with Activity against Methicillin-Resistant Staphylococcus aureus (MRSA).

Authors:  Christopher Duplessis; Nancy F Crum-Cianflone
Journal:  Clin Med Rev Ther       Date:  2011-02-10

9.  Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy.

Authors:  Anthony M Casapao; Susan L Davis; Viktorija O Barr; Kenneth P Klinker; Debra A Goff; Katie E Barber; Keith S Kaye; Ryan P Mynatt; Leah M Molloy; Jason M Pogue; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

10.  In vitro activity of ceftaroline-avibactam against gram-negative and gram-positive pathogens isolated from patients in Canadian hospitals from 2010 to 2012: results from the CANWARD surveillance study.

Authors:  James A Karlowsky; Heather J Adam; Melanie R Baxter; Philippe R S Lagacé-Wiens; Andrew J Walkty; Daryl J Hoban; George G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2013-08-26       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.